Cycle on Aug 17, 2026

I will begin by listing the open threads and registered watches on this topic to understand what has been prioritized or is currently being monitored.

I will read the existing notes to see what findings are already recorded and their respective slugs.

Let's review the stock prices and market views for the key players: UNH, ELV, CI, CVS, HUM, CNC. I will fetch their market views using `market_view` to get a comprehensive public-markets perspective. Let's do this to ground our numbers. Let's call `market_view` for UNH first.

Let's query other tickers. We have ELV, CI, CVS, HUM, CNC. Let's pull ELV first.

Let's pull CI (Cigna Group), CVS, and HUM (Humana). This will give us a very complete picture of the market parameters. Let's do a multi-ticker pull. I'll pull CI first.

Let's pull CVS Health (CVS) and Humana (HUM). These are critical for our comparison. Let's call `market_view` for CVS.

Now let's pull Humana (HUM) and Centene (CNC). Let's call `market_view` for HUM.

Let's pull CNC (Centene Corp) as well. Let's call `market_view` for CNC.

The user wants us to "Adjudicate how US health insurers actually earn their profits — the gap between 'they're hated' and a clear-eyed read of the economics." Let's see: we have existing notes on: 1. `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins` (The Managed Care Profit Engine: Vertical Integration, Services, and the Regulated Margin Myth) 2. `elevance-health-carelon-vertical-integration-internal-margins` (Elevance Health: Carelon and the Internal Profit Engine of Vertical Integration) 3. `cigna-evernorth-pivot-commercial-focus` (Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focus) 4. `centene-medicaid-hbr-2027-policy-risk` (Centene: Medicaid Cost Recovery and the 2027 Work Requirement Policy Risk) 5. `humana-medicare-advantage-margin-compression` (Humana's Medicare Advantage Margin Compression and sicker-member Squeeze) 6. `cvs-health-caremark-aetna-margin-recovery` (CVS Health: Aetna's Margin Recovery and Caremark's Pricing Transition) 7. `unitedhealth-optum-vertical-integration-medicare-advantage` (UnitedHealth and Optum Vertical Integration & Strategic Medicare Advantage Contraction) 8. `pbm-vertical-integration-state-ownership-restrictions` (PBM Vertical Integration: State Ownership Restrictions and the Tennessee Strategic Rewrite) 9. `regulatory-pbm-reform-vertical-integration-cracks` (Regulatory and Legislative Crackdown on PBMs and Vertical Integration) 10. `centene-marketplace-risk-adjustment-wakely-catalyst` (Centene: Marketplace Risk Adjustment and the June Wakely Consulting Catalyst) 11. `medicare-advantage-star-ratings-regulatory-litigation` (Medicare Advantage Star Ratings: CMS Voluntary Redo and the Sector-Wide Litigation Battlefront) Let's do some search on the latest news, regulatory updates, FTC/DOJ actions, CMS MA rules, PBM lawsuits, and earnings transcripts for Q2 2026 for these companies to see what updates we need to make. Wait, let's search for "FTC PBM lawsuit 2026", "Humana 600,000 Medicare Advantage", "UnitedHealth prior authorization target", "Tennessee Fair RX Act lawsuit", and "Eighth Circuit Arkansas PBM". Let's perform a web search first.

Excellent! We have a very specific development on Humana's Medicare Advantage strategic contraction. Wait, let's look at the dates: On its July 29, 2026 earnings call, Humana's CFO Celeste Mellet confirmed that for 2027, plan exits will impact approximately 600,000 members (about 8% of its 7.2 million MA members) as part of its margin recovery strategy to return to at least a 3% sustainable margin. Let's see: we have an existing note on Humana: `humana-medicare-advantage-margin-compression`. We can update this note! Wait, let's look at the details of the other companies too. Let's search for CVS Health Q2 2026 earnings details, specifically about Aetna and Caremark. Let's search for "CVS Health" Q2 2026 earnings call transcript. Let's do a web search.

This is incredibly detailed and solid. We have CVS Health's Q2 2026 earnings reported on August 5, 2026. Let's see: Adjusted EPS was $2.58 (vs $1.87 estimate, a huge beat). Aetna's MBR (medical benefit ratio) fell to 87.4% from 89.9% in the prior year quarter. The Health Care Benefits segment adjusted operating income was $2.4 billion (nearly doubled year-over-year). Wait! The MBR was driven by $500 million of changes in prior year estimates (including Individual Exchange risk adjustment and favorable development), which contributed 140 basis points to the MBR in the quarter. And full-year MBR guidance was tightened to 89.75% ± 25 bps (from 90.5% ± 50 bps). For Caremark (Health Services segment), adjusted operating income was over $1.7 billion, up 10% YoY, but they noted real 340B pressure and a pull-forward of second-half value. This is a perfect update for our CVS Health note: `cvs-health-caremark-aetna-margin-recovery`. Wait, let's look at UnitedHealth Group (UNH) Q2 2026 results. Let's search for "UnitedHealth Group" Q2 2026 earnings transcript or results. Let's do a web search.

This is fantastic. Let's look at the numbers. For UnitedHealth Group: - Q2 2026 adjusted EPS was $6.38 (vs $4.94 estimate, a massive beat). - Medical Care Ratio (MCR) was 86.7% for Q2 2026, down from 89.4% in Q2 2025. - The 86.7% MCR reflects $860 million of net favorable prior period medical development (mostly in-year development). - Increased full-year 2026 operating earnings outlook: - UnitedHealthcare to at least $12.0 billion (from >$10.8 billion) - Optum Health to at least $2.2 billion (from >$2.2 billion or >$1.577 billion previously) - Total Optum operating earnings guidance is >$13.45 billion. - Full year 2026 MCR guidance was updated to 88.1% ± 25 bps. - Medicare margins are projected to finish 2026 above 3%. - Raised full-year 2026 adjusted EPS guidance to $19.50–$20.00 (from >$17.75). Wait, let's look at Elevance Health (ELV) and Carelon. Let's search for "Elevance Health" Q2 2026 earnings call transcript. Let's do a web search.

This is exceptional. Let's look at the numbers for Elevance Health: - Q2 2026 adjusted diluted EPS was $7.45 (vs $6.18 or $6.21 estimate, beating by over $1.20). - Benefit expense ratio (medical loss ratio / MLR) was 89.7%, which increased by 80 bps year over year (from 88.9% in Q2 2025). This was driven by expected elevated medical cost trends in Government businesses, partially offset by improved performance in Individual ACA (Affordable Care Act). - Carelon operating revenue grew 6% to $19.2 billion. - Carelon operating gain totaled $0.9 billion (CarelonRx was $582 million, up 8.6% YoY; Carelon Services was $366 million, down 8.5% YoY). - Health Benefits segment operating gain was $896 million, down 42.6% from $1.56 billion in Q2 2025, showing that the core insurance margin is under pressure, while the services arm (Carelon) generated $948 million (sum of CarelonRx and Carelon Services operating gains), out-earning the core insurance business! This is a perfect, extremely clear-eyed demonstration of the thesis: *the services arm is out-earning the core insurance business!* Carelon's operating gain of $948M exceeded the Health Benefits (insurance) operating gain of $896M. Let's make sure we update `elevance-health-carelon-vertical-integration-internal-margins` with these precise, hard figures. Wait, let's search for Cigna's Q2 2026 earnings details. Specifically Evernorth and commercial focus. Let's do a web search.

Let's analyze Cigna's Q2 2026 earnings: - Reported Q2 2026 earnings on July 30, 2026. - Adjusted EPS was $7.78 (vs $7.58 or $7.60 estimate, beat). - Evernorth Health Services (Cigna's PBM/specialty pharmacy division) generated adjusted revenue of $61.5 billion, a 6% gain over the prior year period. - Cigna Healthcare's medical care ratio (MCR) rose to 84.5% (compared to 83.2% in Q2 2025). This increase was primarily due to prior year risk adjustment benefits within the individual and family plans business recognized in Q2 2025. - Cigna Healthcare pre-tax income grew by 17%, driven by strong pricing discipline in the U.S. Employer business. - Cigna raised its full-year 2026 adjusted EPS guidance to at least $30.45 per share (up $0.10). This is a solid update for Cigna's note `cigna-evernorth-pivot-commercial-focus`. Let's do some research on state-level vertical integration bans, the Tennessee Fair RX Act, the Eighth Circuit Arkansas PBM law, and FTC/DOJ actions. Let's search for "Tennessee Fair RX Act" 2026 lawsuit. Let's do a web search.

This is extremely rich and useful. Let's analyze the details: - On May 22, 2026, Tennessee Governor Bill Lee signed the FAIR Rx Act (Senate Bill 2040 / House Bill 1959) into law. - The FAIR Rx Act prohibits pharmacy benefit managers (PBMs) from owning, operating, or controlling pharmacies licensed in Tennessee. - The law is aimed directly at vertical integration (e.g., CVS Caremark, Cigna Express Scripts). - A recent audit by the Tennessee Department of Commerce and Insurance found that CVS Caremark reimbursed its affiliated pharmacies up to 16,000% more than non-affiliated pharmacies for the same medications! - Three separate lawsuits were filed in the United States District Court for the Middle District of Tennessee: - CVS Caremark filed in May 2026. - Cigna Express Scripts filed in June 2026. - Pharmaceutical Care Management Association (PCMA) filed in June 2026. - The lawsuits argue: - Violates the Dormant Commerce Clause (discriminates against out-of-state companies). - Preempted by federal law (ERISA, Medicare, TRICARE). - Violates the Takings Clause (effectively compelling divestiture of business units). - The law was drafted to take account of constitutional issues encountered by other states, such as Arkansas's Act 624 (which is also facing litigation). The Tennessee law exempted federal/military contracts to avoid TRICARE preemption and omitted statements about protecting local pharmacies to avoid Dormant Commerce Clause issues. - The Eighth Circuit has already limited the scope of Arkansas's PBM law, holding that the "Geographic Coverage Requirements" were preempted by ERISA. Wait, let's look at that. Let's search for "Eighth Circuit" "Arkansas" PBM law 2026 or 2025 decision to get the exact details of the Eighth Circuit ruling. This is extremely important because we have a watch on it! Let's search for "Eighth Circuit" "Arkansas" PBM or "Express Scripts v. Richmond" or "PCMA v. Mulready" or "Eighth Circuit" "Arkansas" Act 624. Let's do a web search.

This is extremely valuable. Let's look closely at the details of these two Eighth Circuit decisions on Arkansas PBM laws: 1. **Flowers v. Caremark PCS Health, LLC**, No. 25-3068 (8th Cir., June 29, 2026): - The Eighth Circuit held that a key element of an Arkansas statute designed to regulate PBMs—specifically, the "Geographic Coverage Requirements"—is preempted by ERISA. - The court ruled that the practical effect of the "Geographic Coverage Requirements" was to "requir[e] PBMs to tailor and retailor their networks — and perhaps even build new brick-and-mortar pharmacies — to comply with a set of exacting particularities." This "bulldozed through [Congressional] objectives" under ERISA. 2. **Express Scripts, Inc. v. Richmond**, No. 25-2529: - This is a pending appeal in the Eighth Circuit regarding a separate Arkansas law (Act 624) that sought to restrict PBMs from owning or operating pharmacies in Arkansas. - The federal district court preliminarily enjoined the law from taking effect due to a likely constitutional violation of the Commerce Clause (as impermissibly regulating interstate commerce) and federal preemption by TRICARE (health insurance for members of the US military and families). - This appeal is still pending! Wait! Let's check the threads and watches we listed earlier: - Watch: `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (id: `019f127c-b0d6-74eb-961b-6040d2ef4913`). The description says: "Monitor the Eighth Circuit's appeal ruling on the preliminary injunction blocking Arkansas's law prohibiting PBM ownership of pharmacies. A ruling upholding the law would pave the way for other states to enforce structural bans on vertical integration." Wait, the appeal is `Express Scripts, Inc. v. Richmond`, which is still pending. Let's see if there are other watches. - Watch: `CMS Star Ratings October 2026 Announcement` (id: `019ea654-ac22-7ec9-beb1-4b8a5ca9e524`). The fire date is `2026-10-15T00:00:00Z` which is in the future (the current date is August 17, 2026). - Watch: `Elevance Health State-Level Medicaid Market Exits` (id: `019f7ea0-b32e-72b2-94d6-653dca807e67`). Let's search if Elevance Health has exited any other state-level Medicaid markets recently. - Watch: `UnitedHealth Group Prior Authorization Volume Reduction Target` (id: `019f7ea0-befc-7d7c-81db-b5e91b0559f9`). The fire date is `2026-12-31T00:00:00Z` which is in the future. - Watch: `Federal Court Ruling on Tennessee Fair RX Act Lawsuits` (id: `019f7ea0-a875-7881-9932-89aecc4ca338`). Since the law was signed in May 2026 and lawsuits were filed in May/June 2026, let's search if there's any ruling on the Tennessee Fair RX Act lawsuits yet. - Watch: `Congress Progress on Patients Before Monopolies Act (PBM Act)` (id: `019eca64-0e4e-79d5-8e2a-b561d5f73584`). Let's do a search on "Elevance Health" Medicaid exits 2026 to see if they exited any other state Medicaid markets. Let's do a web search.

This is incredible! Let's see: we have a highly detailed set of findings on Elevance Health's Medicaid business: - Elevance is exiting the Washington, D.C. Medicaid market effective August 1, 2026. - It covers 250,000 enrollees at a contract value of $8.8 billion over five years (split between Wellpoint D.C. and two other insurers). - CEO Gail Boudreaux announced on the Q2 2026 earnings call that Elevance plans to exit *additional* Medicaid markets over the next 12 to 18 months where they do not see a path to sustainable performance. - Elevance's Medicaid operating margin in 2026 is forecasted to be negative 1.75%. - Total Medicaid enrollment for the "Big Five" has dropped by 6.5% year-over-year (from 36.2 million on June 30, 2025 to 34.0 million on June 30, 2026), driven by H.R. 1 and state redeterminations/work requirements. - This is a perfect update for `elevance-health-carelon-vertical-integration-internal-margins` and also tracks our watch: `Elevance Health State-Level Medicaid Market Exits` (id: `019f7ea0-b32e-72b2-94d6-653dca807e67`). Let's check the watch again: "Track additional state-level Medicaid market exits by Elevance Health (ELV) over the next 12 to 18 months, following its exit from the Washington D.C. market effective August 1, 2026. Multiple exits would signal a structural retreat from government-sponsored risk." Since Gail Boudreaux announced on the July 15, 2026 earnings call that they "expect to exit additional Medicaid markets over the next 12 to 18 months," but actual *additional* state exits have not yet been finalized/announced (they are planned), we should record that this watch is ongoing, but we can note the Q2 earnings confirmation. Wait, let's see if we should record an event on it or just keep it open. It's an ongoing watch, so we can keep it open. Wait, let's look at the first watch: - `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (id: `019f127c-b0d6-74eb-961b-6040d2ef4913`). Wait, we found that on June 29, 2026, in *Flowers v. Caremark PCS Health, LLC* (No. 25-3068), the Eighth Circuit held that the "Geographic Coverage Requirements" of the Arkansas law were preempted by ERISA. Wait, let's check if there is an appeal ruling on Act 624 (which is the law prohibiting PBM ownership of pharmacies, challenged in *Express Scripts, Inc. v. Richmond*, No. 25-2529). Let's search for "Express Scripts v. Richmond" 2026 or "Act 624" Eighth Circuit to see if there is any update on this. Let's do a web search.

This is excellent. Let's look at the timeline and the status: - In August 2025, a federal district court judge (Judge Miller) preliminarily enjoined Arkansas's Act 624 (which prohibits PBMs from owning or operating pharmacies in the state) because of a likely constitutional violation of the dormant Commerce Clause and TRICARE preemption. - The state of Arkansas appealed this decision to the Eighth Circuit in *Express Scripts, Inc. v. Richmond*, No. 25-2529. - As of July/August 2026, the appeal is still pending in the Eighth Circuit. Note that the Eighth Circuit's recent June 29, 2026 decision in *Flowers v. Caremark PCS Health, LLC* (No. 25-3068)—which held that Arkansas's "Geographic Coverage Requirements" were preempted by ERISA—did *not* decide the ownership-ban appeal in *Express Scripts v. Richmond*. - This means the watch `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (id: `019f127c-b0d6-74eb-961b-6040d2ef4913`) is still active and has *not* fired yet. We will keep it open. Wait, let's look at another watch: - `Federal Court Ruling on Tennessee Fair RX Act Lawsuits` (id: `019f7ea0-a875-7881-9932-89aecc4ca338`). Let's search if there is any federal district court ruling or injunction on the Tennessee Fair RX Act lawsuits yet (CVS, Express Scripts, and PCMA lawsuits filed in May/June 2026). Let's do a web search.

Ah! The search budget is spent. That's perfectly fine; we have a wealth of high-quality, precise evidence from our searches and market views to write incredibly detailed updates and resolve any relevant threads. Let's review the active threads and watches: - Thread/Watch `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law`: Still pending. - Thread/Watch `Federal Court Ruling on Tennessee Fair RX Act Lawsuits`: Still pending. - Thread/Watch `Elevance Health State-Level Medicaid Market Exits`: We have some updates! Gail Boudreaux confirmed on the July 15, 2026 earnings call that they are exiting D.C. Medicaid effective August 1, 2026, and plan to exit additional markets over the next 12 to 18 months. We will keep this watch open as it is ongoing. - Thread/Watch `UnitedHealth Group Prior Authorization Volume Reduction Target`: Ongoing. - Thread/Watch `CMS Star Ratings October 2026 Announcement`: Ongoing. - Thread/Watch `Congress Progress on Patients Before Monopolies Act (PBM Act)`: Ongoing. Let's look at the topics we want to write findings for. We need to write notes (or update existing ones) using the stable slugs. Wait! Let's check which slugs we have and what updates we should make: 1. `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins` (The Managed Care Profit Engine: Vertical Integration, Services, and the Regulated Margin Myth) - This is the high-level thesis note. We should update it with the latest Q2 2026 findings across the board, showing that core health insurance margins are being compressed (e.g., Elevance's Health Benefits operating gain fell 42.6% to $896M) while services arms (e.g., Carelon at $948M, Evernorth at $61.5B revenue, Optum operating earnings raising to at least $13.45B) are out-earning or driving the growth of the business. This beautifully illustrates that the regulated insurance margin is a myth, and the real profit engines are the vertical services arms. 2. `elevance-health-carelon-vertical-integration-internal-margins` (Elevance Health: Carelon and the Internal Profit Engine of Vertical Integration) - We will update this note with ELV's Q2 2026 results (reported July 15, 2026): adjusted diluted EPS of $7.45 (beat estimate of $6.18/6.21); benefit expense ratio of 89.7% (up 80 bps YoY); Health Benefits segment operating gain of $896M (down 42.6%); CarelonRx operating gain of $582M (up 8.6%); Carelon Services operating gain of $366M (down 8.5%). Note that Carelon's combined operating gain of $948M exceeded the Health Benefits segment's operating gain of $896M! Also add details about the D.C. Medicaid market exit (effective August 1, 2026) and planned future exits over the next 12 to 18 months due to negative 1.75% margins in Medicaid. 3. `unitedhealth-optum-vertical-integration-medicare-advantage` (UnitedHealth and Optum Vertical Integration & Strategic Medicare Advantage Contraction) - Update with UNH's Q2 2026 results (reported July 16, 2026): adjusted EPS of $6.38 (beat estimate of $4.94); MCR of 86.7% (reflecting $860M of net favorable prior period development); raised full-year adjusted EPS guidance to $19.50–$20.00; raised UnitedHealthcare operating earnings guidance to at least $12.0B and Optum Health to at least $2.2B (total Optum operating earnings guidance is >$13.45B). 4. `humana-medicare-advantage-margin-compression` (Humana's Medicare Advantage Margin Compression and sicker-member Squeeze) - Update with HUM's Q2 2026 results (reported July 29, 2026): CFO Celeste Mellet confirmed plan exits for 2027 impacting approximately 600,000 members (about 8% of its 7.2 million MA members) as part of its margin recovery strategy to return to at least a 3% sustainable margin. 5. `cvs-health-caremark-aetna-margin-recovery` (CVS Health: Aetna's Margin Recovery and Caremark's Pricing Transition) - Update with CVS's Q2 2026 results (reported August 5, 2026): adjusted EPS of $2.58 (beat estimate of $1.87); Aetna's MBR fell to 87.4% (down from 89.9% YoY), driven by $500M of favorable development (140 bps impact); tightened full-year MBR guidance to 89.75% ± 25 bps. Health Services (Caremark) adjusted operating income was over $1.7B (up 10% YoY), but they noted real 340B pressure and a pull-forward of second-half value. 6. `cigna-evernorth-pivot-commercial-focus` (Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focus) - Update with Cigna's Q2 2026 results (reported July 30, 2026): adjusted EPS of $7.78 (beat estimate of $7.58); Evernorth Health Services generated adjusted revenue of $61.5B (up 6% YoY); medical care ratio rose to 84.5% (up from 83.2% YoY); raised full-year adjusted EPS guidance to at least $30.45 per share. 7. `pbm-vertical-integration-state-ownership-restrictions` (PBM Vertical Integration: State Ownership Restrictions and the Tennessee Strategic Rewrite) - Update with the Tennessee FAIR Rx Act (signed May 22, 2026 by Governor Lee), prohibiting PBMs from owning pharmacies in Tennessee. Add details on the three lawsuits filed in May/June 2026 by CVS Caremark, Cigna Express Scripts, and PCMA. Also note the Eighth Circuit's June 29, 2026 decision in *Flowers v. Caremark PCS Health, LLC* (No. 25-3068) preempting Arkansas's "Geographic Coverage Requirements" under ERISA, while the separate appeal on PBM ownership bans (*Express Scripts v. Richmond*, No. 25-2529) remains pending. Let's write these notes! Wait, let's make sure our markdown format is correct: - No YAML frontmatter - The title is the first `# ` heading - The slug is passed as the slug parameter - Include a `## Sources` block at the bottom with links and short descriptions. - Carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Use wikilinks `[[slug]]` to link other findings. Let's update the first note: `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins`. Let's draft it. Wait, let's check what the existing note has first. We don't have the full body of the existing notes, but we can update them based on the core thesis and the new Q2 2026 data. Let's call `write_note` for each slug. I will write the update for `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins` first. Let's make sure the content is highly detailed and analytical, citing our market views and transcripts.I will now write the updated note for `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins` to reflect the latest Q2 2026 earnings results and structural trends. This note anchors the core thesis that the regulated insurance margin is a myth, and the real profit engines are the vertically integrated services arms.

Now

I will now write the updated note for Elevance Health (`elevance-health-carelon-vertical-integration-internal-margins`), incorporating the exact Q2 2026 segment margins and the newly announced Washington, D.C. Medicaid market exit and planned future retreats.

I will now write the updated note for UnitedHealth Group and Optum (`unitedhealth-optum-vertical-integration-medicare-advantage`), adding the exact Q2 2026 earnings beat, the favorable prior period development, and the raised segment guidance.

I will now write the updated note for Humana (`humana-medicare-advantage-margin-compression`), detailing the confirmed 2027 plan exits affecting 600,000 Medicare Advantage members as part of its margin recovery strategy.

I will now write the updated note for CVS Health (`cvs-health-caremark-aetna-margin-recovery`), detailing the Q2 2026 earnings beat, Aetna's MBR recovery, and Caremark's 340B pressure.

I will now write the updated note for Cigna (`cigna-evernorth-pivot-commercial-focus`), detailing the Q2 2026 earnings beat, Evernorth's revenue growth, and the raised guidance.

I will now write the updated note for PBM vertical integration and state-level restrictions (`pbm-vertical-integration-state-ownership-restrictions`), incorporating the newly enacted Tennessee FAIR Rx Act, the three PBM lawsuits, and the latest Eighth Circuit ERISA preemption ruling.

I have updated all relevant notes to reflect the latest Q2 2026 earnings results, segment margins, and structural regulatory shifts. I will now call `finish_cycle` to complete this research cycle.

I have successfully completed the research cycle on the economics and structural mechanics of US health insurers. ### Summary of Key Findings from this Cycle: 1. **The Regulated Margin Myth vs. Services Reality**: Core health insurance margins are facing significant compression in government risk pools. For example, **Elevance Health's (ELV)** Health Benefits (insurance) operating gain fell 42.6% to $896 million in Q2 2026. However, its vertically integrated services division, **Carelon**, generated $948 million in operating gain, completely out-earning the core insurance segment and demonstrating where the real profit engine sits (`[[elevance-health-carelon-vertical-integration-internal-margins]]`). 2. **Defensive Contractions in Medicare Advantage & Medicaid**: Insurers are aggressively prioritizing margin over enrollment volume. **Humana (HUM)** confirmed it will exit select MA plans in 2027, affecting roughly 600,000 members (8% of its base) to defend its 2028 margin target of at least 3% (`[[humana-medicare-advantage-margin-compression]]`). Meanwhile, Elevance is exiting the Washington, D.C. Medicaid market and planning further state-level exits over the next 12 to 18 months due to a negative 1.75% margin forecast in Medicaid. 3. **Resiliency of Favorable Reserves**: **UnitedHealth Group (UNH)** and **CVS Health (CVS)** both delivered massive Q2 2026 earnings beats supported by significant prior period medical development ($860 million for UNH and $500 million for CVS), which artificially flattered their medical care ratios and insulated them from sector-wide cost trends (`[[unitedhealth-optum-vertical-integration-medicare-advantage]]`, `[[cvs-health-caremark-aetna-margin-recovery]]`). 4. **The Escalating State-Level War on Vertical Integration**: On May 22, 2026, Tennessee enacted the **FAIR Rx Act**, banning PBMs from owning pharmacies in the state. This represents an existential challenge to the vertically integrated model of CVS Caremark and Cigna Express Scripts. PBMs have filed three separate federal lawsuits challenging the law, while the Eighth Circuit recently limited the scope of a similar Arkansas law under ERISA preemption (`[[pbm-vertical-integration-state-ownership-restrictions]]`).